The Journal of Bone and Joint Surgery (American). 2004;86:41-55
© 2004 The Journal of Bone and Joint Surgery, Inc.
Use of Bone Morphogenetic Proteins for Musculoskeletal Applications
An Overview
Michael A. Mont, MD,
Phillip S. Ragland, MD,
Bridget Biggins, BA,
Gary Friedlaender, MD,
Tushar Patel, MD,
Stephen Cook, MD,
Gracia Etienne, MD, PhD,
Andrew Shimmin, MD,
Robyn Kildey, BS,
David C. Rueger, PhD and
Thomas A. Einhorn, MD
Corresponding author: Michael A. Mont, MD Center for Joint Preservation
and Reconstruction, Rubin Institute for Advanced Orthopedics, Sinai
Hospital of Baltimore, 2401 West Belvedere Avenue, Baltimore, MD 21215.
E-mail address:
rhondamont@aol.com
| The first 150 words of the full text of this article appear below. |
 |
Introduction
|
|---|
Since Marshall Urist's original description, in 1965, of the potential of
demineralized bone matrix to induce bone formation, the medical community has
anticipated the development of osteogenic
therapies1.
Following this discovery, researchers sought to identify and isolate these
growth factors, specifically bone morphogenetic proteins (BMPs). Reddi and
Huggins first characterized these important molecules involved in bone
formation in 1973, and, in 1982, Sampath and Reddi developed a rat
subcutaneous assay for BMP activity that measures bone
formation2. They
found that BMPs initiate the bone-healing cascade through the recruitment of
and interactions with mesenchymal stem cells found in surrounding tissues,
including fascial planes, periosteum, peripheral blood, bone marrow, and
cancellous bone. Several, but not all, of the fifteen human BMPs described to
date have been found to bind to stem-cell receptors, triggering proliferation
and differentiation, and to result in bone regeneration and repair.
Once various BMPs were successfully isolated, . . . [Full Text of this Article]

CiteULike Connotea Del.icio.us Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Q. Cui, Z. Xiao, X. Li, K. J. Saleh, and G. Balian
Use of Genetically Engineered Bone-Marrow Stem Cells to Treat Femoral Defects: An Experimental Study
J. Bone Joint Surg. Am.,
November 1, 2006;
88(suppl_3):
167 - 172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J. Seeherman, K. Azari, S. Bidic, L. Rogers, X. J. Li, J. O. Hollinger, and J. M. Wozney
rhBMP-2 Delivered in a Calcium Phosphate Cement Accelerates Bridging of Critical-Sized Defects in Rabbit Radii
J. Bone Joint Surg. Am.,
July 1, 2006;
88(7):
1553 - 1565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Wang, C. C. Clark, and C. T. Brighton
Up-Regulation of Bone Morphogenetic Proteins in Cultured Murine Bone Cells with Use of Specific Electric Fields
J. Bone Joint Surg. Am.,
May 1, 2006;
88(5):
1053 - 1065.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Mont, L. C. Jones, and D. S. Hungerford
Nontraumatic Osteonecrosis of the Femoral Head: Ten Years Later
J. Bone Joint Surg. Am.,
May 1, 2006;
88(5):
1117 - 1132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. B. Betz, V. M. Betz, A. Nazarian, C. G. Pilapil, M. S. Vrahas, M. L. Bouxsein, L. C. Gerstenfeld, T. A. Einhorn, and C. H. Evans
Direct Percutaneous Gene Delivery to Enhance Healing of Segmental Bone Defects
J. Bone Joint Surg. Am.,
February 1, 2006;
88(2):
355 - 365.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|